Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nano RED
AddedFeb 19, 2024
UpdatedJun 18, 2026
Nano RED

Nano RED

Nano RED: Pioneering precision delivery tech for next-gen RNA and immunotherapeutics.

HQ
Wauwatosa, WI, US
Founded
2015
Overview
Compare
Fundraising
Employees

Nano RED is dedicated to pioneering precision delivery technologies aimed at advancing the next generation of RNA and immunotherapeutics. The company focuses on developing innovative solutions to enhance the efficacy and safety of therapeutic delivery, targeting the biotech and pharmaceutical markets.

Nano RED has made significant strides in the biotech industry, contributing to the development of cutting-edge therapies. Their technology has the potential to revolutionize treatment paradigms, making them a notable player in the field of RNA and immunotherapy.

Nano RED - Similar Companies

Nanotransfer logo

Nanotransfer

nanotransfer.bio

ReNAgade Therapeutics logo

ReNAgade Therapeutics

Optimeos Life Sciences logo

Optimeos Life Sciences

optimeos.com

Nextrna Therapeutics logo

Nextrna Therapeutics

Nano Cures logo

Nano Cures

nanocures.com

NanoPharmaceuticals logo

NanoPharmaceuticals

Redona Therapeutics logo

Redona Therapeutics

redonatx.com

Advanced NanoTherapies logo

Advanced NanoTherapies

Nanosur logo

Nanosur

nanosur.com

Locanabio logo

Locanabio

Rnaimmune logo

Rnaimmune

rnaimmune.com

Nucleonics logo

Nucleonics

Atom Bioworks logo

Atom Bioworks

atombioworks.com

Sixfold Bioscience logo

Sixfold Bioscience

sixfold.bio

Kylin Therapeutics logo

Kylin Therapeutics

Nano RED - Quick Facts

Who are Nano RED's competitors?

Companies similar to Nano RED include Nanotransfer, ReNAgade Therapeutics, Optimeos Life Sciences and Nextrna Therapeutics.

When was Nano RED founded?

Nano RED was founded in 2015.

Where is Nano RED's headquarters located?

Nano RED's headquarters is located in Wauwatosa, WI, US.

When was Nano RED's last funding round?

Nano RED's most recent funding round was for $75k (USD) in January 2022.

How much has Nano RED raised to-date?

As of Jan 10, 2022, Nano RED has raised a total of $321.7k (USD).

How many employees does Nano RED have?

Nano RED has 7 employees as of Feb 4, 2024.

Nano RED - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Licensing
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Delivery
  • Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified